155 results match your criteria: "Center for Alzheimer's Disease Research[Affiliation]"
Brain
January 2020
Department of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Targeted overexpression of angiotensin-converting enzyme (ACE), an amyloid-β protein degrading enzyme, to brain resident microglia and peripheral myelomonocytes (ACE10 model) substantially diminished Alzheimer's-like disease in double-transgenic APPSWE/PS1ΔE9 (AD+) mice. In this study, we explored the impact of selective and transient angiotensin-converting enzyme overexpression on macrophage behaviour and the relative contribution of bone marrow-derived ACE10 macrophages, but not microglia, in attenuating disease progression. To this end, two in vivo approaches were applied in AD+ mice: (i) ACE10/GFP+ bone marrow transplantation with head shielding; and (ii) adoptive transfer of CD115+-ACE10/GFP+ monocytes to the peripheral blood.
View Article and Find Full Text PDFFront Mol Neurosci
March 2019
Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Bio-X Institutes, Shanghai Jiao Tong University, Shanghai, China.
Many human neurodegenerative diseases are associated with amyloid fibril formation. Inhibition of amyloid formation is of importance for therapeutics of the related diseases. However, the development of selective potent amyloid inhibitors remains challenging.
View Article and Find Full Text PDFTetrahedron Lett
January 2019
Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, CA 90095, United States.
This study describes our development of a microfluidic reaction scheme for the synthesis of fused indoline ring systems found in several bioactive compounds. We have utilized a continuous-flow microfluidic reactor for the reaction of hydrazines with latent aldehydes through the interrupted Fischer indolization reaction to form fused indoline and azaindoline products. We have identified optimal conditions and evaluated the scope of this microfluidic reaction using various hydrazine and latent aldehyde surrogates.
View Article and Find Full Text PDFMethods Mol Biol
June 2019
Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, Los Angeles, CA, USA.
Analyses of bloodborne nanoscale extracellular vesicles (nsEVs) have shown tremendous promise in enabling the development of noninvasive blood-based clinical diagnostic tests, predicting and monitoring the efficacy of treatment programs, and identifying new drug targets in the context of health conditions such as cancer and Alzheimer's disease. In this chapter we present a protocol for generating global nsEV proteomic profiles that can further the utility of nsEV analysis for the above biomedical applications by enlightening us of differences in protein abundance across normal and disease state nsEVs. This protocol features the use of magnetic particle-based immunoprecipitation to enrich highly purified populations of nsEVs directly from plasma or serum samples.
View Article and Find Full Text PDFSci Rep
December 2018
The Drug Discovery Lab, Mary S. Easton Center for Alzheimer's Disease Research, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
We describe here the results from the testing of a small molecule first-in-class apolipoprotein E4 (ApoE4)-targeted sirtuin1 (SirT1) enhancer, A03, that increases the levels of the neuroprotective enzyme SirT1 while not affecting levels of neurotoxic sirtuin 2 (SirT2) in vitro in ApoE4-transfected cells. A03 was identified by high-throughput screening (HTS) and found to be orally bioavailable and brain penetrant. In vivo, A03 treatment increased SirT1 levels in the hippocampus of 5XFAD-ApoE4 (E4FAD) Alzheimer's disease (AD) model mice and elicited cognitive improvement while inducing no observed toxicity.
View Article and Find Full Text PDFBrain Imaging Behav
August 2019
Division of Child & Adolescent Psychiatry, Semel Institute For Neuroscience, University of California, Los Angeles, 760 Westwood Plaza, 58-227, Los Angeles, CA, 90095, USA.
H magnetic resonance spectroscopy (MRS) can reveal changes in brain biochemistry in vivo in humans and has been applied to late onset Alzheimer disease (AD). Carriers of mutations for autosomal dominant Alzheimer disease (ADAD) may show changes in levels of metabolites prior to the onset of clinical symptoms. Proton MR spectra were acquired at 1.
View Article and Find Full Text PDFJ Mol Biol
May 2018
The Drug Discovery Lab, Mary S. Easton Center for Alzheimer's Disease Research, Department of Neurology, University of California, Los Angeles, CA, USA. Electronic address:
The aspartyl protease BACE1 (BACE) has emerged as an appealing target for reduction of amyloid-β in Alzheimer's disease. The clinical fate of active-site BACE inhibitors may depend on potential side effects related to enzyme and substrate selectivity. One strategy to reduce this risk is through development of allosteric inhibitors that interact with and modulate the Loop F region unique to BACE1.
View Article and Find Full Text PDFNeurobiol Aging
May 2018
Department of Neurology, UCLA, Los Angeles, CA, USA; Easton Center for Alzheimer's Disease Research, Los Angeles, CA, USA; Memory and Aging Center, Department of Neurology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
Fast, inexpensive, and noninvasive identification of Alzheimer's disease (AD) before clinical symptoms emerge would augment our ability to intervene early in the disease. Individuals with fully penetrant genetic mutations causing autosomal dominant Alzheimer's disease (ADAD) are essentially certain to develop the disease, providing a unique opportunity to examine biomarkers during the preclinical stage. Using a generalization task that has previously shown to be sensitive to medial temporal lobe pathology, we compared preclinical individuals carrying ADAD mutations to noncarrying kin to determine whether generalization (the ability to transfer previous learning to novel but familiar recombinations) is vulnerable early, before overt cognitive decline.
View Article and Find Full Text PDFAlzheimers Dement (N Y)
January 2017
Department of Psychiatry and Human Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Introduction: Alzheimer's disease (AD) incidence is disproportionately high in African Americans, yet, recruitment of this community to AD clinical trials is challenging.
Methods: We compared 47 African Americans and 78 whites in their willingness to enroll in a hypothetical preclinical AD trial and examined barriers and facilitators in their decision making.
Results: African American race (OR = 0.
Brain Behav Immun
January 2018
Department of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, 127 S. San Vicente Blvd., Los Angeles, CA 90048, USA; Department of Biomedical Sciences, Division of Applied Cell Biology and Physiology, Cedars-Sinai Medical Center, 127 S. San Vicente Blvd., Los Angeles, CA 90048, USA. Electronic address:
Osteopontin (OPN), a matricellular immunomodulatory cytokine highly expressed by myelomonocytic cells, is known to regulate immune cell migration, communication, and response to brain injury. Enhanced cerebral recruitment of monocytes achieved through glatiramer acetate (GA) immunization or peripheral blood enrichment with bone marrow (BM)-derived CD115 monocytes (Mo) curbs amyloid β-protein (Aβ) neuropathology and preserves cognitive function in murine models of Alzheimer's disease (ADtg mice). To elucidate the beneficial mechanisms of these immunomodulatory approaches in AD, we focused on the potential role of OPN in macrophage-mediated Aβ clearance.
View Article and Find Full Text PDFNeurosci Lett
September 2017
Department of Neurology, Washington University in St. Louis, 660 S. Euclid Ave, St. Louis, MO, 63110, USA.
We describe clinical and biomarker findings in an index patient with the onset of Alzheimer's disease (AD) symptoms at age 57 and a family history consistent with an autosomal dominant pattern of inheritance. She had the atypical early features of visual agnosia and prosopagnosia followed by hoarding behavior and Parkinsonism. Structural MRI revealed global atrophy that was most severe in the lateral temporal lobes and insular cortex bilaterally.
View Article and Find Full Text PDFMol Cell Neurosci
September 2017
The Buck Institute for Research on Aging, 8001 Redwood Blvd, Novato, CA 94945, USA. Electronic address:
The apolipoprotein E ε4 allele is the single most important genetic risk factor associated with Alzheimer's disease (AD). Tau phosphorylation and hyperphosphorylation is an underlying feature of AD and is regulated by specific kinases and phosphatases. Among phosphatases, protein phosphatase 2A (PP2A) is the principal tau dephosphorylating enzyme in the brain.
View Article and Find Full Text PDFJ Alzheimers Dis
May 2018
Alzheimer's Disease Research Center, Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA.
Background: The presenilin-1 protein (PS1) is the catalytic unit of γ-secretase implicated in the production of abnormally long forms of amyloid-β (Aβ), including Aβ42, proteins thought critical in the pathogenesis of Alzheimer's disease (AD). In AD of autosomal dominant inheritance, the majority of pathogenic mutations have been found in the PSEN1 gene within which the location of the mutation can provide clues as to the mechanism of pathogenesis.
Objective: To describe clinical features of two novel mutations in the transmembrane portion 1 (TMD-1) of PSEN1 as well as biochemical features in one and neuropathological findings in the other.
Alzheimers Res Ther
May 2017
University of Pennsylvania, Philadelphia, PA, USA.
Background: Mild cognitive impairment (MCI) has an uncertain etiology and prognosis and may be challenging for clinicians to discuss with patients and families. Amyloid imaging may aid specialists in determining MCI etiology and prognosis, but creates novel challenges related to disease labeling.
Methods: We convened a workgroup to formulate recommendations for clinicians providing care to MCI patients.
Dement Geriatr Cogn Dis Extra
October 2016
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, Calif, USA; Mary S. Easton Center for Alzheimer's Disease Research, Los Angeles, Calif, USA; Department of Neurology, Indiana University, Indianapolis, Ind, USA.
Introduction: We investigated the effect dance experience may have on cortical gray matter thickness and cognitive performance in elderly participants with and without mild cognitive impairment (MCI).
Methods: 39 cognitively normal and 48 MCI elderly participants completed a questionnaire regarding their lifetime experience with music, dance, and song. Participants identified themselves as either dancers or nondancers.
Alzheimer Dis Assoc Disord
December 2017
*Layton Aging & Alzheimer's Disease Center, Oregon Health & Science University, Portland, OR †Alzheimer's Disease Center, University of California, Davis, Sacramento ‡Memory and Aging Center, University of California, San Francisco, San Francisco ¶Mary S. Easton Center for Alzheimer's Disease Research, University of California ¶¶Alzheimer's Disease Research Center, University of Southern California, Los Angeles ∥∥Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA §Johns Hopkins University Alzheimer's Disease Research Center, Baltimore, MD ∥Knight Alzheimer's Disease Research Center, Washington University, St Louis, MO #School of Pharmacy, Hampton University, Hampton, VA **Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, PA ‡‡Mayo Clinic, Jacksonville, FL §§Alzheimer's Disease Center Emory University, Atlanta, GA ††Cognitive Neurology and Alzheimer's Disease Center, Northwestern University ##Department of Family Medicine and Rush Alzheimer's Disease Center, Rush University, Chicago, IL.
Introduction: Racial and ethnic groups are under-represented among research subjects who assent to brain donation in Alzheimer disease research studies. There has been little research on this important topic. Although there are some studies that have investigated the barriers to brain donation among African American study volunteers, there is no known research on the factors that influence whether or not Asians or Latinos are willing to donate their brains for research.
View Article and Find Full Text PDFNeurobiol Aging
November 2016
Department of Neurology, Keck School of Medicine of USC Center for the Health Professionals, Los Angeles, CA, USA; Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Mary S. Easton Center for Alzheimer's Disease Research, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address:
The mechanisms underlying presenilin 1 (PSEN1) mutation-associated spastic paraparesis (SP) are not clear. We compared diffusion and volumetric magnetic resonance measures between 3 persons with SP associated with the A431E mutation and 7 symptomatic persons with PSEN1 mutations without SP matched for symptom duration. We performed amyloid imaging and central motor and somatosensory conduction studies in 1 subject with SP.
View Article and Find Full Text PDFInt J Alzheimers Dis
May 2016
Drug Discovery Laboratory, Department of Neurology, Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, CA 90095, USA.
Diagnostic assays that leverage bloodborne neuron-derived (neuronal) nanoscale extracellular vesicles (nsEVs) as "windows into the brain" can predict incidence of Alzheimer's Disease (AD) many years prior to onset. Beyond diagnostics, bloodborne neuronal nsEVs analysis may have substantial translational impact by revealing mechanisms of AD pathology; such knowledge could enlighten new drug targets and lead to new therapeutic approaches. The potential to establish three-dimensional nsEV analysis methods that characterize highly purified bloodborne nsEV populations in method of enrichment, cell type origin, and protein or RNA abundance dimensions could bring this promise to bear by yielding nsEV "omics" datasets that uncover new AD biomarkers and enable AD therapeutic development.
View Article and Find Full Text PDFTetrahedron Lett
May 2016
Drug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, CA 90095.
This study describes our development of a novel and efficient procedure for C-O bond formation under mild conditions, for coupling heteroaryl chlorides with phenols or primary aliphatic alcohols. We utilized a continuous-flow microfluidic reactor for C-O bond formation in electron-deficient pyrimidines and pyridines in a much more facile manner with a cleaner reaction profile, high yield, quick scalability and without the need for the transition metal catalyst. This approach can be of general utility to make C-O bond containing intermediates of industrial importance in a continuous and safe manner.
View Article and Find Full Text PDFJ Phys Chem B
July 2016
Department of Neurology, David Geffen School of Medicine at UCLA, Mary S. Easton Center for Alzheimer's Disease Research at UCLA, and Brain Research Institute and Molecular Biology Institute, University of California, 635 Charles Young Drive South, Los Angeles, California 90095, United States.
Neurobiol Aging
March 2016
Penn Neurodegenerative Disease Ethics and Policy Program, Department of Medicine, Penn Memory Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Penn Neurodegenerative Disease Ethics and Policy Program, Department of Medical Ethics and Health Policy, Penn Memory Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Preclinical Alzheimer's disease (AD) clinical trials may require participants to learn if they meet biomarker enrollment criteria. To examine whether this requirement will impact trial recruitment, we presented 132 older community volunteers who self-reported normal cognition with 1 of 2 hypothetical informed consent forms (ICFs) describing an AD prevention clinical trial. Both ICFs described amyloid Positron Emission Tomography scans.
View Article and Find Full Text PDFJ Clin Exp Neuropsychol
December 2016
h Center for the Study of Retired Athletes of the University of North Carolina, Chapel Hill, NC , USA.
Objective: Various concussion characteristics and personal factors are associated with cognitive recovery in athletes. We developed an index based on concussion frequency, severity, and timeframe, as well as cognitive reserve (CR), and we assessed its predictive power regarding cognitive ability in retired professional football players.
Method: Data from 40 retired professional American football players were used in the current study.
J Neuropathol Exp Neurol
March 2016
From the Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, Department of Neurology, Los Angeles, California (JMR, DWN, YZ, AN, GC, MFM, ST, HVV); Memory and Aging Center, Keck School of Medicine of University of Southern California, Los Angeles, California (JMR); Department of Biostatistics, University of Washington, Seattle, Washington (SM); Department of Pathology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California (DWN, ST, HVV); Semel Institute for Neuroscience and Human Behavior, Los Angeles, California (GC,VVB); Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (SW, M-MM, EHB, DRG); Advocate Lutheran General Hospital, Park Ridge, Illinois (DRG); Department of Medicine, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois (DRG); Department of Pathology, University of Michigan, Ann Arbor, Michigan (AOF-H); VA Ann Arbor Healthcare System, Geriatrics Research, Education, and Clinical Center, Ann Arbor, Michigan (RLA); and Department of Neurology, University of Michigan, Ann Arbor, Michigan (RLA).
Alzheimer disease (AD) represents a genetically heterogeneous entity. To elucidate neuropathologic features of autosomal dominant AD ([ADAD] due to PSEN1, APP, or PSEN2 mutations), we compared hallmark AD pathologic findings in 60 cases of ADAD and 120 cases of sporadic AD matched for sex, race, ethnicity, and disease duration. Greater degrees of neuritic plaque and neurofibrillary tangle formation and cerebral amyloid angiopathy (CAA) were found in ADAD (p values < 0.
View Article and Find Full Text PDFJ Am Chem Soc
February 2016
Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93106, United States.
Evidence suggests that oligomers of the 42-residue form of the amyloid β-protein (Aβ), Aβ42, play a critical role in the etiology of Alzheimer's disease (AD). Here we use high resolution atomic force microscopy to directly image populations of small oligomers of Aβ42 that occur at the earliest stages of aggregation. We observe features that can be attributed to a monomer and to relatively small oligomers, including dimers, hexamers, and dodecamers.
View Article and Find Full Text PDFJ Am Chem Soc
February 2016
The State Key Laboratory of Molecular Engineering of Polymers and Department of Macromolecular Science, Fudan University, Shanghai 200433, China.
Protein microtubule is a significant self-assembled architecture found in nature with crucial biological functions. However, mimicking protein microtubules with precise structure and controllable self-assembly behavior remains highly challenging. In this work, we demonstrate that by using dual supramolecular interactions from a series of well-designed ligands, i.
View Article and Find Full Text PDF